COMPANY
Anebulo Pharmaceuticals
Anebulo is developing selonabant, a reversal agent for cannabis induced toxicities. From company website Source · Oct 12, 2026
Timeline
- Trial start Phase 1: I.V. Selonabant in Healthy Adult Subjects source ↗
- Trial start —: Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression source ↗
- Trial start Phase 2: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test source ↗
Upcoming milestones
- Dec 30, 2026 (ESTIMATED) · · Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression · NCT06017622
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06017622 | Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression | Not listed | Recruiting | Jun 1, 2023 | Dec 30, 2026 (estimated) |
| NCT07211607 | I.V. Selonabant in Healthy Adult Subjects | Phase 1 | Completed | Sep 22, 2025 | May 6, 2026 (actual) |
| NCT05282797 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test | Phase 2 | Completed | Dec 15, 2021 | Aug 26, 2023 (actual) |
NIH awards 2
- NIH award 5U01DA059995-02 FY2025: $994,300 awarded for that fiscal year; activity U01 (OTHER_NIH); PI CUNDY, KENNETH; recipient as written: ANEBULO PHARMACEUTICALS, INC., LAKEWAY, TX. Development of an intravenous CB source ↗
- NIH award 1U01DA059995-01 FY2024: $892,290 awarded for that fiscal year; activity U01 (OTHER_NIH); PI CUNDY, KENNETH; recipient as written: ANEBULO PHARMACEUTICALS, INC., LAKEWAY, TX. Development of an intravenous CB source ↗
Raises and investors new
- Raise Private raise (SEC Form D): $15.0M sold; issuer “Anebulo Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗